Jim Cramer Discusses Novo Nordisk A/S (NVO) And CVS

We recently published 8 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed.

Novo Nordisk A/S (NYSE:NVO) revealed last week that it would cut 9,000 jobs as part of a cost-cutting push through which it expects to save $1.3 billion. The push comes at a time the firm has struggled to compete with Eli Lilly in the lucrative weight loss drug market. While Cramer has not discussed weight loss drug companies recently, he has commented on the sector’s effects on the food industry. He believes that weight loss drugs have transformed the food sector, and food companies should consider mergers to cut their costs. As for Novo Nordisk A/S (NYSE:NVO), the CNBC TV host has previously opined that the firm has been “poorly run.” Here are his recent thoughts about the firm:

“I know and I think that, look I think that maybe if you don’t advertise, maybe, then maybe people go with that one. Because remember, CVS put you on that one. That’s the Wegovy there.”

Photo by Laurynas Me on Unsplash

Here are Cramer’s previous thoughts about Novo Nordisk A/S (NYSE:NVO):

“They’re very poorly run. I don’t know this new CEO, but they are incredibly poorly run, and I’m not going to bet that they suddenly are going to change stripes… They take my breath away about how bad, how poorly they are.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.